Trump moves to reclassify medical marijuana, impacting prediction markets

Trump’s move to reclassify medical marijuana to Schedule III has shifted prediction markets. The likelihood of marijuana being rescheduled by December 31 is now at 42.8%, down from 62% yesterday.

Market reaction

Short and long-term expectations have split sharply. The June 30 contract has dropped to 9.5% YES, showing skepticism about near-term action. The December 31 contract fell too but remains well above the June number. This term structure suggests traders expect regulatory delays but still see resolution as likely before year-end.

Why it matters

Trading volume is $46,442 in USDC daily for the December 31 contract. The order book is thin: just $775 can shift prices by 5 points. The largest recent swing was an 8-point spike followed by a settle-back, consistent with reactive trading in a low-liquidity environment.

The Trump administration’s directive partially answers the market question, but uncertainty around implementation timelines is keeping prices depressed. A YES share at 43¢ would pay 2.33x if rescheduling happens by December 31, and traders are clearly pricing in meaningful delay risk.

What to watch

The DEA’s next steps matter most, particularly any Federal Register filings or expedited hearing announcements. Terrance Cole’s statements as DEA Administrator will directly affect the timeline, along with any action from the Attorney General’s office or Congress.

API access

Get prediction market intelligence as a structured API feed. Early access waitlist.